Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dextran + glucose is a combination product composed of dextran (a high-molecular-weight glucose polymer used as a plasma volume expander and antithrombotic) and glucose (dextrose, used to provide calories and osmotic support). This drug is primarily used as an intravenous solution for plasma volume expansion in hypovolemia due to trauma, surgery, burns, or dehydration when blood products are unavailable or not feasible. Dextran acts osmotically to retain fluid in the vascular compartment, improves microcirculation, and has antithrombotic effects by reducing platelet aggregation and blood viscosity. Glucose, in this formulation, serves as an energy source and osmotic agent. The combination is not commonly used today due to safer alternatives but is approved for particular specialized scenarios such as microsurgical procedures and as a hemodiluting agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dextran + glucose.